Cargando…

Bortezomib in the management of multiple myeloma

Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laubach, Jacob P, Mitsiades, Constantine S, Hideshima, Teru, Schlossman, Robert, Chauhan, Dharminder, Munshi, Nikhil, Ghobrial, Irene, Carreau, Nicole, Anderson, Kenneth C, Richardson, Paul G
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004671/ https://www.ncbi.nlm.nih.gov/pubmed/21188129

Ejemplares similares

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
por: Richardson, Paul G, et al.
Publicado: (2012)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
por: Jakubikova, Jana, et al.
Publicado: (2016)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2020)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity
por: McMillin, Douglas W., et al.
Publicado: (2010)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy
por: Yun, Charles, et al.
Publicado: (2015)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uudc6tner95j7e9sr29ngjncuo